In accordance with European Union regulations, the Public Procurement Act has been in force since January 1, 2017, and will be fully applied from July 1 of the same year for all goods or services whose price has not already been defined by a specific law or regulation. <\/p>\n
The criterion of the most economically advantageous tender becomes the exclusive criterion for selecting a bidder for all goods or services whose price has not already been defined by a specific law or regulation, with the note that price still has a decisive influence on the selection (up to 90% of the tender), while other criteria set by the contracting authority account for at least 10% of the tender.<\/p>\n
Although, in principle, this is a very effective solution for the procurement of goods and services by government bodies, a number of problems arise when it comes to the healthcare sector.<\/p>\n","protected":false},"excerpt":{"rendered":"
If price were to continue accounting for 90% of the selection criteria when choosing a bidder, in the worst-case scenario this could undermine market competition, potentially resulting in drug shortages and violating patients\u2019 constitutional rights to choose the best therapy and medication.<\/p>\n","protected":false},"author":2,"featured_media":23918,"parent":0,"template":"","meta":{"_acf_changed":false},"tags":[112],"kategorije-novosti":[103],"class_list":["post-24821","novosti","type-novosti","status-publish","has-post-thumbnail","hentry","tag-news-archive","kategorije-novosti-positions","wpbf-post"],"acf":[],"yoast_head":"\n